Claim Ledger
71% answered
Did management answer the analysts?
12 analyst questions audited, 1 evaded or deflected.
View Claim Ledger →
Apollohosp Ltd — Q1 FY25
Apollo Hospitals delivered a strong Q1 FY25 with consolidated revenue of INR 5,086 crore (+15% YoY) and EBITDA of INR 675 crore (+33% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Apollo Hospitals delivered a strong Q1 FY25 with consolidated revenue of INR 5,086 crore (+15% YoY) and EBITDA of INR 675 crore (+33% YoY). PAT surged 83% YoY to INR 305 crore. The hospital business saw inpatient volumes grow 11% YoY and occupancy rise 600bps to 68%, driven by insurance penetration (now 47% of revenue) and medical team expansion (102 doctors added). Apollo HealthCo reported positive EBITDA of INR 23 crore, with 24/7 digital losses narrowing to INR 97 crore. Management guided for 100bps margin expansion in hospitals over 3-4 quarters and 24/7 breakeven in 6-7 quarters. Risk: slower-than-expected ARPOB recovery due to higher medical case mix and potential disruption from Bangladesh political situation (2% of revenue).
अपोलो हॉस्पिटल्स ने पहली तिमाही में अच्छा प्रदर्शन किया। कुल कमाई 5,086 करोड़ रुपये रही, जो पिछले साल से 15% ज्यादा है। कमाई में से खर्चे निकालने के बाद बचा मुनाफा (EBITDA) 675 करोड़ रुपये रहा, जो 33% बढ़ा। शुद्ध मुनाफा (PAT) 305 करोड़ रुपये रहा, जो 83% ज्यादा है। अस्पतालों में मरीजों की संख्या 11% बढ़ी और बिस्तरों का उपयोग 68% हो गया। इसकी वजह बीमा का बढ़ता उपयोग (अब 47% कमाई) और 102 नए डॉक्टर हैं। Apollo HealthCo ने 23 करोड़ रुपये का मुनाफा कमाया। कंपनी का कहना है कि अगले 3-4 तिमाहियों में अस्पतालों का मुनाफा और बढ़ेगा। जोखिम: मरीजों के इलाज का खर्च बढ़ सकता है और बांग्लादेश की स्थिति से 2% कमाई पर असर पड़ सकता है।
Promises0 met · 2 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Risks
3 risks
Risk Intelligence
Bangladesh political situation impacting international patients
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Occupancy
68%
+600bps YoY
Group occupancy rose from 62% to 68% year-on-year, driven by higher inpatient volumes and insurance penetration.
Inpatient Volume Growth
11%
+11% YoY
IP volumes grew 11% year-on-year, with strong performance across all markets and specialties.
Insurance Revenue Share
47%
+400bps YoY
Insurance patient revenue as a share of hospital revenue increased to 47%, up from ~43% last year.
24/7 Digital Cash Losses
INR 97 crore
-36% YoY
Digital platform cash losses (ex-ESOP) reduced from INR 152 crore to INR 97 crore year-on-year.
What Changed vs Last Quarter
NEW
Hospital margin expansion of 100bps over 3-4 quarters
Management expects healthcare services EBITDA margin to expand by 100 basis points over the next 3-4 quarters, driven by volume growth, case mix improvement, and cost optimization.
NEW
ARPOB growth of 7% for FY25
Management guided for ARPOB increase of 7% for the full year, supported by tariff revision of 4%, better case mix, and international patient recovery.
UPDATED
Apollo 24/7 digital breakeven in 6-7 quarters
The digital segment is on track to achieve breakeven within the next six to seven quarters, supported by GMV growth and cost control.
UPDATED
500-550 new pharmacy stores in FY25
Apollo HealthCo plans to add 500-550 new offline pharmacy stores in FY25, with Q1 impacted by election delays but pace expected to pick up.
DROPPED
Healthcare services revenue growth >15% in FY25
Driven by volume growth, network expansion, and better asset utilization.
DROPPED
Healthcare services EBITDA margin expansion of 150 bps in FY25
Targeting 25% margin by end of FY25 through cost optimization and surgical volume growth.
NEW RISK
Bangladesh political situation impacting international patients
Bangladesh contributes ~30% of international patient revenue (2% of total revenue). Recent political issues have caused a drop in volumes, though management expects recovery.
NEW RISK
Slower ARPOB recovery due to higher medical case mix
ARPOB grew only 2% YoY due to a higher proportion of medical admissions. Management expects improvement but there is risk if surgical volumes do not pick up as anticipated.
NEW RISK
New hospital bed additions may pressure margins
Operationalization of four new hospitals (1,500 beds) over next five quarters could reduce EBITDA margins by 100-150bps from FY25 exit levels.
RISK GONE
New hospital ramp-up may delay margin recovery
Four new hospitals with 1,500 beds to be operationalized by calendar 2025-26; initial costs could pressure margins.
RISK GONE
Doctor hiring costs may not yield immediate volume benefits
150 new doctors hired in FY24; full revenue contribution expected only by Q2 FY25, posing near-term margin risk.
RISK GONE
Inventory rationalization impact on pharmacy distribution
Lower inventory buildup reduced pharmacy distribution sales by ~INR 150 crore in Q4; growth recovery depends on store-level execution.
RISK GONE
Competitive pressure in Nashik market
Nashik hospital remains a drag on western region occupancy due to multiple competitors and low-paying patient mix.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q4 FY24
Targeting GMV of INR 1,700 crore per quarter and take rate improvement from 4% to 8%.
Mentioned in Q2 FY24, Q3 FY24
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
Mentioned in Q1 FY24, Q2 FY24
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
Mentioned in Q2 FY24, Q4 FY24
Targeting 25% margin by end of FY25 through cost optimization and surgical volume growth.
Mentioned in Q3 FY24, Q4 FY24
Driven by volume growth, network expansion, and better asset utilization.
Fast read
Guidance and risk preview
Management expects healthcare services EBITDA margin to expand by 100 basis points over the next 3-4 quarters, driven by volume growth, case mix im...
Bangladesh contributes ~30% of international patient revenue (2% of total revenue).
View Risks →